Switching sales: Investigating the financial impacts of FDA’s priority vouchers
The second of a two part-series on priority review vouchers investigates trends in the vibrant market of million-dollar vouchers and how companies use them.
Explore our marketing solutions
Genomics has been identified as the top emerging pharmaceutical industry trend for 2024, with its growth attributed to the increasing prevalence of chronic diseases, plummeting DNA sequencing costs, and increasing funding for genomics. Despite an optimistic outlook for 2024, the industry growth is predicted to be below 2022 levels primarily due to geopolitical conflicts, inflation, and drug pricing pressures.
